Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06399952 · ClinicalTrials.gov registry record
Baker Gordon Syndrome Natural History Study
A clinical trial of Sleep Disorder and Rare Diseases, sponsored by University of Missouri-Columbia.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT06399952: Recruiting study of Sleep Disorder and Rare Diseases, sponsored by University of Missouri-Columbia.
NCT06399952 is a study of Sleep Disorder and Rare Diseases that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 50 participants, below the 160-participant average among 22 other Sleep Disorder trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06399952, a study of Sleep Disorder and Rare Diseases, is actively recruiting participants, sponsored by University of Missouri-Columbia.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to conduct a prospective, longitudinal assessment of the natural clinical progression of children and adults with Synaptotagmin1-Associated Neurodevelopmental Disorder also known as Baker Gordon Syndrome (BAGOS). This will be performed by acquiring baseline measurements and developing effective outcome measures and diagnostic tools for the disorder, to prepare the healthcare system for future clinical trials.
Primary Outcome
Collection of demographic data, BAGOS-related medical history, past medical and surgical history, current medication, history of immunizations and family medical history.
Conditions Studied
Interventions
- GENETIC Whole Genome Sequencing
- DIAGNOSTIC_TEST Brain Magnetic Resonance Imaging (MRI)
- OTHER Induced Pluripotential Stem Cells
Study Locations (1)
Missouri
- University of Missouri Columbia - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-04-30 |
| Est. Completion | 2026-05-05 |
What NCT06399952 shows while recruiting
NCT06399952 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 160-participant average among 22 other Sleep Disorder trials with a reported enrollment target (69% lower).
The record links to 7 conditions, with Sleep Disorder appearing as the primary indexed condition, and to 3 interventions - of which Whole Genome Sequencing is the first listed.
NCT06399952 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06399952 about?
NCT06399952 is a clinical study titled "Baker Gordon Syndrome Natural History Study". The goal of this study is to conduct a prospective, longitudinal assessment of the natural clinical progression of children and adults with Synaptotagmin1-Associated Neurodevelopmental Disorder also known as Baker Gordon Syndrome (BAGOS). This will be performed by acquiring baseline measurements and...
What is the current status of trial NCT06399952?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2024-04-30. Estimated completion is 2026-05-05.
What conditions does trial NCT06399952 study?
This clinical trial studies the following conditions: Sleep Disorder, Rare Diseases, Development Delay, Motor Delay, Epilepsy, Generalized.
What interventions are being tested in trial NCT06399952?
The interventions under investigation include: Whole Genome Sequencing (GENETIC), Brain Magnetic Resonance Imaging (MRI) (DIAGNOSTIC_TEST), Induced Pluripotential Stem Cells (OTHER).
Who is sponsoring clinical trial NCT06399952?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06399952 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sleep Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06399952's enrollment target sits among peer trials
50 15th of 22 higher than 7 of 22 other Sleep Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sleep Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
RECRUITING · Phase 3
-
Study of Disrupted Sleep in Somali Americans
RECRUITING
-
Do Endotypes Predict Response and Sequelae in OSA Patients
RECRUITING · Phase 2
-
NIA_Improving Function and Well-being by Improving Patient Memory: Transdiagnostic Sleep and Circadian Treatment
RECRUITING · NA
-
Home Apnea Testing in CHildren Trial
RECRUITING · NA
-
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI